Laura James
Concepts (560)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acetaminophen | 59 | 2023 | 352 | 11.990 |
Why?
| Analgesics, Non-Narcotic | 25 | 2021 | 143 | 5.000 |
Why?
| Drug Overdose | 15 | 2019 | 171 | 2.920 |
Why?
| Liver | 23 | 2020 | 1228 | 2.880 |
Why?
| Hepatocytes | 15 | 2018 | 206 | 2.370 |
Why?
| Liver Failure, Acute | 11 | 2018 | 63 | 2.140 |
Why?
| Liver Regeneration | 9 | 2019 | 57 | 2.010 |
Why?
| Alanine Transaminase | 17 | 2023 | 150 | 1.330 |
Why?
| MicroRNAs | 4 | 2020 | 379 | 1.290 |
Why?
| Proton Pump Inhibitors | 7 | 2024 | 91 | 1.190 |
Why?
| Acetylcysteine | 13 | 2019 | 118 | 1.180 |
Why?
| Cytochrome P-450 CYP2E1 | 4 | 2020 | 119 | 1.180 |
Why?
| Adolescent | 45 | 2024 | 6968 | 1.170 |
Why?
| Mitochondria, Liver | 10 | 2015 | 86 | 1.150 |
Why?
| Male | 83 | 2024 | 27693 | 1.130 |
Why?
| Cytochrome P-450 CYP3A | 3 | 2020 | 85 | 1.080 |
Why?
| Child | 42 | 2024 | 7462 | 1.040 |
Why?
| Oxidative Stress | 12 | 2023 | 923 | 1.040 |
Why?
| Humans | 102 | 2024 | 54415 | 0.940 |
Why?
| Chromatography, High Pressure Liquid | 10 | 2016 | 392 | 0.930 |
Why?
| Child, Preschool | 29 | 2024 | 4228 | 0.910 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 62 | 0.890 |
Why?
| Attitude | 2 | 2021 | 80 | 0.880 |
Why?
| Cytokines | 8 | 2012 | 688 | 0.880 |
Why?
| Asthma | 4 | 2022 | 301 | 0.880 |
Why?
| Proteins | 4 | 2016 | 377 | 0.820 |
Why?
| Rape | 1 | 2022 | 25 | 0.820 |
Why?
| Vitamin D Deficiency | 1 | 2022 | 49 | 0.810 |
Why?
| Female | 62 | 2024 | 28667 | 0.810 |
Why?
| Animals | 41 | 2023 | 14668 | 0.800 |
Why?
| Crime Victims | 1 | 2022 | 43 | 0.800 |
Why?
| Sex Offenses | 1 | 2022 | 86 | 0.750 |
Why?
| Health Facilities | 1 | 2021 | 45 | 0.740 |
Why?
| Inflammation | 3 | 2020 | 669 | 0.700 |
Why?
| Naphthalenes | 9 | 2018 | 124 | 0.700 |
Why?
| Health Services Accessibility | 2 | 2021 | 429 | 0.700 |
Why?
| Cytochrome P-450 CYP1A2 | 4 | 2020 | 49 | 0.690 |
Why?
| Indoles | 9 | 2018 | 292 | 0.690 |
Why?
| Liver Diseases | 4 | 2023 | 84 | 0.680 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2011 | 219 | 0.680 |
Why?
| Mice | 29 | 2023 | 6439 | 0.670 |
Why?
| Bronchoconstriction | 1 | 2019 | 8 | 0.670 |
Why?
| Cysteine | 6 | 2017 | 62 | 0.660 |
Why?
| Mitochondria | 2 | 2020 | 456 | 0.640 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 21 | 0.640 |
Why?
| Aspartate Aminotransferases | 8 | 2015 | 57 | 0.630 |
Why?
| Bronchodilator Agents | 1 | 2019 | 76 | 0.610 |
Why?
| Radius | 1 | 2018 | 30 | 0.610 |
Why?
| Immunoassay | 1 | 2016 | 30 | 0.560 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 82 | 0.560 |
Why?
| Serum | 1 | 2016 | 39 | 0.560 |
Why?
| Gastroesophageal Reflux | 4 | 2018 | 51 | 0.550 |
Why?
| Anti-Bacterial Agents | 6 | 2023 | 832 | 0.540 |
Why?
| Dose-Response Relationship, Drug | 12 | 2019 | 1519 | 0.530 |
Why?
| Cystic Fibrosis | 1 | 2018 | 162 | 0.510 |
Why?
| Infant | 21 | 2022 | 3886 | 0.510 |
Why?
| HMGB1 Protein | 2 | 2021 | 17 | 0.510 |
Why?
| Keratin-18 | 2 | 2021 | 15 | 0.510 |
Why?
| Reactive Nitrogen Species | 3 | 2015 | 35 | 0.500 |
Why?
| Mice, Inbred C57BL | 15 | 2019 | 2026 | 0.500 |
Why?
| Proliferating Cell Nuclear Antigen | 4 | 2019 | 79 | 0.500 |
Why?
| Bile Acids and Salts | 1 | 2015 | 79 | 0.500 |
Why?
| Lung | 1 | 2019 | 528 | 0.500 |
Why?
| Young Adult | 16 | 2021 | 4334 | 0.490 |
Why?
| Mass Spectrometry | 4 | 2014 | 326 | 0.480 |
Why?
| Mice, Inbred Strains | 7 | 2019 | 199 | 0.480 |
Why?
| Tyrosine | 4 | 2007 | 131 | 0.480 |
Why?
| Isoniazid | 1 | 2014 | 38 | 0.470 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 134 | 0.460 |
Why?
| Carnitine | 1 | 2014 | 72 | 0.450 |
Why?
| Autoantibodies | 1 | 2014 | 134 | 0.440 |
Why?
| Trifluoperazine | 1 | 2012 | 8 | 0.430 |
Why?
| Disease Models, Animal | 7 | 2020 | 1650 | 0.430 |
Why?
| Viperidae | 1 | 2012 | 5 | 0.420 |
Why?
| Crotalid Venoms | 1 | 2012 | 9 | 0.420 |
Why?
| Antivenins | 1 | 2012 | 11 | 0.420 |
Why?
| Anti-Ulcer Agents | 3 | 2007 | 21 | 0.420 |
Why?
| Sensitivity and Specificity | 9 | 2016 | 931 | 0.420 |
Why?
| Immunoglobulin Fragments | 1 | 2012 | 17 | 0.420 |
Why?
| Snake Bites | 1 | 2012 | 17 | 0.410 |
Why?
| Tomography, X-Ray Computed | 1 | 2018 | 1241 | 0.410 |
Why?
| Echinomycin | 1 | 2011 | 7 | 0.400 |
Why?
| Hospitalization | 4 | 2017 | 708 | 0.390 |
Why?
| Cannabinoids | 5 | 2013 | 105 | 0.390 |
Why?
| Spider Venoms | 1 | 2011 | 6 | 0.390 |
Why?
| Half-Life | 6 | 2019 | 93 | 0.390 |
Why?
| Hypersensitivity | 1 | 2012 | 81 | 0.380 |
Why?
| Necrosis | 6 | 2019 | 209 | 0.380 |
Why?
| Phosphoric Diester Hydrolases | 1 | 2011 | 30 | 0.380 |
Why?
| Enzyme Inhibitors | 5 | 2019 | 442 | 0.380 |
Why?
| Adult | 20 | 2024 | 14363 | 0.370 |
Why?
| Indocyanine Green | 1 | 2010 | 37 | 0.370 |
Why?
| Macrolides | 3 | 2022 | 16 | 0.350 |
Why?
| Prospective Studies | 11 | 2021 | 2547 | 0.350 |
Why?
| Middle Aged | 16 | 2024 | 13036 | 0.340 |
Why?
| Models, Biological | 7 | 2024 | 807 | 0.330 |
Why?
| Metabolomics | 3 | 2015 | 133 | 0.330 |
Why?
| Triazoles | 3 | 2022 | 118 | 0.330 |
Why?
| Methamphetamine | 3 | 2013 | 258 | 0.320 |
Why?
| Protein Binding | 5 | 2017 | 710 | 0.320 |
Why?
| Central Nervous System Stimulants | 3 | 2013 | 281 | 0.320 |
Why?
| Homeostasis | 3 | 2020 | 233 | 0.310 |
Why?
| Chemokines | 2 | 2010 | 94 | 0.310 |
Why?
| Research Subjects | 2 | 2019 | 57 | 0.300 |
Why?
| Chemokine CCL2 | 2 | 2005 | 77 | 0.300 |
Why?
| Community-Based Participatory Research | 2 | 2021 | 212 | 0.300 |
Why?
| Imines | 3 | 2019 | 15 | 0.300 |
Why?
| Poisoning | 2 | 2006 | 27 | 0.290 |
Why?
| Benzoquinones | 3 | 2019 | 33 | 0.290 |
Why?
| Area Under Curve | 8 | 2019 | 195 | 0.290 |
Why?
| Interleukin-8 | 3 | 2012 | 97 | 0.280 |
Why?
| Tandem Mass Spectrometry | 6 | 2018 | 249 | 0.280 |
Why?
| Interleukin-6 | 3 | 2012 | 312 | 0.280 |
Why?
| Arkansas | 6 | 2024 | 2183 | 0.280 |
Why?
| Caustics | 1 | 2006 | 5 | 0.280 |
Why?
| Burns, Chemical | 1 | 2006 | 9 | 0.280 |
Why?
| Pandemics | 2 | 2022 | 582 | 0.280 |
Why?
| Hypoxia-Inducible Factor 1 | 1 | 2006 | 6 | 0.270 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 24 | 0.270 |
Why?
| Signal Transduction | 5 | 2019 | 1736 | 0.270 |
Why?
| Cell Death | 4 | 2020 | 225 | 0.270 |
Why?
| Cross-Sectional Studies | 3 | 2022 | 1705 | 0.270 |
Why?
| Antidotes | 4 | 2011 | 35 | 0.260 |
Why?
| Infant, Premature | 4 | 2016 | 349 | 0.260 |
Why?
| Liver Function Tests | 2 | 2002 | 46 | 0.260 |
Why?
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 44 | 0.260 |
Why?
| Reactive Oxygen Species | 3 | 2015 | 474 | 0.250 |
Why?
| Gene Expression Regulation | 3 | 2016 | 1063 | 0.250 |
Why?
| Predictive Value of Tests | 5 | 2016 | 997 | 0.250 |
Why?
| Peroxynitrous Acid | 2 | 2007 | 48 | 0.250 |
Why?
| Infant, Newborn | 10 | 2018 | 3002 | 0.240 |
Why?
| Cytochrome P-450 Enzyme System | 3 | 2015 | 212 | 0.240 |
Why?
| Up-Regulation | 4 | 2018 | 491 | 0.240 |
Why?
| Ion Channels | 1 | 2004 | 76 | 0.240 |
Why?
| Glutathione | 4 | 2023 | 329 | 0.240 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2024 | 51 | 0.240 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 39 | 0.230 |
Why?
| Gastric Acidity Determination | 1 | 2003 | 12 | 0.230 |
Why?
| Biotransformation | 4 | 2015 | 108 | 0.230 |
Why?
| Immunohistochemistry | 3 | 2012 | 1090 | 0.230 |
Why?
| Aminoglycosides | 1 | 2023 | 21 | 0.230 |
Why?
| Chromatography, Liquid | 6 | 2018 | 245 | 0.230 |
Why?
| Glucuronosyltransferase | 3 | 2017 | 128 | 0.230 |
Why?
| Medication Adherence | 1 | 2024 | 142 | 0.220 |
Why?
| Administration, Oral | 7 | 2018 | 467 | 0.220 |
Why?
| Pilot Projects | 4 | 2021 | 781 | 0.210 |
Why?
| Granzymes | 2 | 2020 | 12 | 0.210 |
Why?
| Pneumonia, Bacterial | 1 | 2022 | 27 | 0.210 |
Why?
| Digestive System | 1 | 2002 | 18 | 0.210 |
Why?
| Vitamins | 1 | 2022 | 69 | 0.210 |
Why?
| Community-Acquired Infections | 1 | 2022 | 42 | 0.210 |
Why?
| Membrane Glycoproteins | 1 | 2003 | 262 | 0.210 |
Why?
| Designer Drugs | 2 | 2013 | 28 | 0.210 |
Why?
| Aged | 7 | 2024 | 10034 | 0.200 |
Why?
| Gastrointestinal Agents | 1 | 2002 | 36 | 0.200 |
Why?
| Obesity | 2 | 2022 | 1177 | 0.200 |
Why?
| Vitamin D | 1 | 2022 | 94 | 0.200 |
Why?
| Phosphatidic Acids | 2 | 2019 | 8 | 0.200 |
Why?
| Photography | 1 | 2021 | 37 | 0.200 |
Why?
| Anti-Infective Agents | 2 | 2013 | 109 | 0.190 |
Why?
| Microsomes, Liver | 4 | 2015 | 209 | 0.190 |
Why?
| Dried Blood Spot Testing | 2 | 2018 | 5 | 0.190 |
Why?
| Metabolic Clearance Rate | 5 | 2018 | 74 | 0.190 |
Why?
| Sexual Behavior | 1 | 2022 | 128 | 0.190 |
Why?
| United States | 7 | 2022 | 5292 | 0.190 |
Why?
| Universities | 1 | 2022 | 169 | 0.190 |
Why?
| Healthcare Disparities | 1 | 2024 | 275 | 0.190 |
Why?
| Oxidation-Reduction | 6 | 2023 | 362 | 0.190 |
Why?
| Bayes Theorem | 3 | 2012 | 119 | 0.190 |
Why?
| Gastrointestinal Diseases | 1 | 2002 | 134 | 0.190 |
Why?
| Hydroxyurea | 1 | 2020 | 31 | 0.180 |
Why?
| Polymorphism, Genetic | 2 | 2018 | 196 | 0.180 |
Why?
| Aged, 80 and over | 4 | 2021 | 3409 | 0.180 |
Why?
| Histamine H2 Antagonists | 3 | 2005 | 25 | 0.170 |
Why?
| Students | 1 | 2022 | 223 | 0.170 |
Why?
| Heart Arrest | 1 | 2022 | 163 | 0.170 |
Why?
| Cell Line | 3 | 2017 | 1122 | 0.170 |
Why?
| Substance-Related Disorders | 3 | 2022 | 679 | 0.170 |
Why?
| Retrospective Studies | 8 | 2024 | 6554 | 0.170 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.170 |
Why?
| Statistics, Nonparametric | 2 | 2011 | 230 | 0.170 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2022 | 591 | 0.170 |
Why?
| Recombinant Proteins | 4 | 2018 | 537 | 0.170 |
Why?
| Lipids | 1 | 2020 | 173 | 0.170 |
Why?
| Prothrombin Time | 3 | 2005 | 19 | 0.170 |
Why?
| Binding Sites | 2 | 2017 | 427 | 0.170 |
Why?
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 5 | 0.170 |
Why?
| Diagnosis, Differential | 3 | 2015 | 1143 | 0.170 |
Why?
| ortho-Aminobenzoates | 1 | 2019 | 9 | 0.170 |
Why?
| Carbachol | 1 | 2019 | 37 | 0.170 |
Why?
| Respiratory Hypersensitivity | 1 | 2019 | 18 | 0.170 |
Why?
| Liver Cirrhosis | 1 | 2021 | 220 | 0.170 |
Why?
| Organ Culture Techniques | 1 | 2019 | 53 | 0.170 |
Why?
| Stress, Physiological | 1 | 2020 | 191 | 0.170 |
Why?
| Child, Hospitalized | 1 | 2019 | 33 | 0.160 |
Why?
| Mice, Knockout | 4 | 2011 | 945 | 0.160 |
Why?
| Disclosure | 1 | 2019 | 42 | 0.160 |
Why?
| Drug Administration Schedule | 4 | 2021 | 406 | 0.160 |
Why?
| Bacterial Infections | 2 | 2017 | 103 | 0.160 |
Why?
| Hepatitis, Viral, Human | 1 | 2018 | 6 | 0.160 |
Why?
| Cannabidiol | 1 | 2019 | 39 | 0.160 |
Why?
| Case-Control Studies | 3 | 2018 | 1212 | 0.160 |
Why?
| Time Factors | 5 | 2013 | 3216 | 0.160 |
Why?
| Oropharynx | 2 | 2009 | 15 | 0.160 |
Why?
| Health Status Disparities | 1 | 2021 | 201 | 0.160 |
Why?
| Body Weight | 3 | 2018 | 588 | 0.160 |
Why?
| Phosphatidate Phosphatase | 1 | 2018 | 11 | 0.160 |
Why?
| Ampicillin | 1 | 2018 | 7 | 0.160 |
Why?
| Research Personnel | 1 | 2019 | 69 | 0.160 |
Why?
| Albuterol | 1 | 2019 | 58 | 0.160 |
Why?
| Protein Biosynthesis | 2 | 2017 | 271 | 0.160 |
Why?
| Hepatitis, Autoimmune | 1 | 2018 | 29 | 0.160 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2018 | 8 | 0.160 |
Why?
| Education, Nonprofessional | 1 | 2017 | 8 | 0.150 |
Why?
| Human Experimentation | 1 | 2017 | 11 | 0.150 |
Why?
| Information Dissemination | 1 | 2019 | 102 | 0.150 |
Why?
| Sirtuin 1 | 1 | 2017 | 28 | 0.150 |
Why?
| Teicoplanin | 1 | 2017 | 4 | 0.150 |
Why?
| Sulfonamides | 1 | 2019 | 141 | 0.150 |
Why?
| Teaching Materials | 1 | 2017 | 32 | 0.150 |
Why?
| 3' Untranslated Regions | 1 | 2017 | 55 | 0.150 |
Why?
| Treatment Outcome | 6 | 2019 | 5579 | 0.150 |
Why?
| Mass Screening | 1 | 2021 | 374 | 0.150 |
Why?
| Patient Participation | 1 | 2018 | 72 | 0.150 |
Why?
| Absorptiometry, Photon | 1 | 2018 | 172 | 0.150 |
Why?
| Health Services Research | 1 | 2018 | 163 | 0.150 |
Why?
| Substance Abuse Detection | 2 | 2022 | 95 | 0.140 |
Why?
| Reading | 1 | 2017 | 85 | 0.140 |
Why?
| Rural Population | 2 | 2021 | 606 | 0.140 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 550 | 0.140 |
Why?
| Electrochemical Techniques | 1 | 2016 | 15 | 0.140 |
Why?
| Anthropometry | 2 | 2015 | 101 | 0.140 |
Why?
| Comprehension | 1 | 2017 | 113 | 0.140 |
Why?
| Nuclear Proteins | 1 | 2018 | 258 | 0.140 |
Why?
| Saliva | 1 | 2016 | 62 | 0.140 |
Why?
| Liver Failure | 1 | 2016 | 23 | 0.140 |
Why?
| Age Factors | 3 | 2015 | 1193 | 0.130 |
Why?
| Amphetamine | 2 | 2013 | 42 | 0.130 |
Why?
| Vitamin A | 1 | 2016 | 19 | 0.130 |
Why?
| Nitric Oxide Synthase Type I | 2 | 2015 | 16 | 0.130 |
Why?
| Injections, Intravenous | 3 | 2012 | 152 | 0.130 |
Why?
| Point-of-Care Systems | 1 | 2016 | 64 | 0.130 |
Why?
| Blood Proteins | 2 | 2006 | 100 | 0.130 |
Why?
| Blood Pressure Monitors | 1 | 2015 | 10 | 0.130 |
Why?
| Taurodeoxycholic Acid | 1 | 2015 | 7 | 0.130 |
Why?
| Glycodeoxycholic Acid | 1 | 2015 | 7 | 0.130 |
Why?
| Glycochenodeoxycholic Acid | 1 | 2015 | 7 | 0.130 |
Why?
| Keratin-8 | 1 | 2015 | 3 | 0.130 |
Why?
| Caffeine | 1 | 2016 | 76 | 0.130 |
Why?
| Styrene | 1 | 2015 | 10 | 0.130 |
Why?
| Biomedical Research | 1 | 2019 | 247 | 0.130 |
Why?
| Guanidines | 1 | 2015 | 38 | 0.130 |
Why?
| Delayed-Action Preparations | 2 | 2012 | 51 | 0.130 |
Why?
| Prodrugs | 2 | 2012 | 35 | 0.130 |
Why?
| Solid Phase Extraction | 2 | 2013 | 12 | 0.130 |
Why?
| Bone Density | 1 | 2018 | 439 | 0.130 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 83 | 0.130 |
Why?
| Tablets | 3 | 2013 | 31 | 0.130 |
Why?
| Cross-Over Studies | 2 | 2012 | 254 | 0.130 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.120 |
Why?
| Breast Neoplasms | 1 | 2024 | 1246 | 0.120 |
Why?
| Immunity, Innate | 1 | 2016 | 114 | 0.120 |
Why?
| Administration, Intravenous | 3 | 2019 | 73 | 0.120 |
Why?
| Nitrates | 2 | 2011 | 47 | 0.120 |
Why?
| Environmental Pollutants | 1 | 2015 | 106 | 0.120 |
Why?
| Famotidine | 2 | 2005 | 11 | 0.120 |
Why?
| Cells, Cultured | 4 | 2017 | 1724 | 0.120 |
Why?
| Discriminant Analysis | 1 | 2014 | 33 | 0.120 |
Why?
| Least-Squares Analysis | 1 | 2014 | 52 | 0.120 |
Why?
| Superoxide Dismutase | 2 | 2011 | 127 | 0.110 |
Why?
| Fentanyl | 1 | 2014 | 37 | 0.110 |
Why?
| Urinalysis | 1 | 2014 | 49 | 0.110 |
Why?
| Wounds, Stab | 1 | 2013 | 7 | 0.110 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2012 | 434 | 0.110 |
Why?
| Cyclosporine | 2 | 2011 | 67 | 0.110 |
Why?
| Cannabis | 2 | 2019 | 150 | 0.110 |
Why?
| Basal Ganglia | 1 | 2013 | 27 | 0.110 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.110 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.110 |
Why?
| Neck Injuries | 1 | 2013 | 25 | 0.110 |
Why?
| Nonlinear Dynamics | 2 | 2012 | 22 | 0.110 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 28 | 0.110 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2012 | 19 | 0.110 |
Why?
| Mycophenolic Acid | 1 | 2012 | 19 | 0.110 |
Why?
| Cohort Studies | 3 | 2019 | 1526 | 0.110 |
Why?
| Kinetics | 4 | 2018 | 696 | 0.110 |
Why?
| Myoglobin | 1 | 2013 | 26 | 0.110 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2012 | 541 | 0.110 |
Why?
| Receptors, Phospholipase A2 | 1 | 2012 | 20 | 0.110 |
Why?
| Indicators and Reagents | 1 | 2012 | 43 | 0.110 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 28 | 0.110 |
Why?
| Dinoprostone | 1 | 2012 | 56 | 0.110 |
Why?
| Neurotoxicity Syndromes | 1 | 2013 | 55 | 0.110 |
Why?
| Flushing | 1 | 2012 | 4 | 0.110 |
Why?
| Piperacillin | 1 | 2012 | 24 | 0.110 |
Why?
| Permeability | 1 | 2012 | 83 | 0.110 |
Why?
| Fasting | 1 | 2012 | 77 | 0.100 |
Why?
| Seroepidemiologic Studies | 2 | 2022 | 50 | 0.100 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2012 | 21 | 0.100 |
Why?
| Blood Specimen Collection | 1 | 2012 | 38 | 0.100 |
Why?
| Erythema | 1 | 2012 | 44 | 0.100 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 117 | 0.100 |
Why?
| Metronidazole | 1 | 2012 | 35 | 0.100 |
Why?
| Exanthema | 1 | 2012 | 33 | 0.100 |
Why?
| Heart Septal Defects, Ventricular | 1 | 2012 | 43 | 0.100 |
Why?
| Insulin | 1 | 2014 | 502 | 0.100 |
Why?
| Pruritus | 1 | 2012 | 44 | 0.100 |
Why?
| T-Lymphocytes | 1 | 2014 | 379 | 0.100 |
Why?
| Lipopolysaccharides | 1 | 2013 | 217 | 0.100 |
Why?
| Cardiopulmonary Bypass | 1 | 2012 | 99 | 0.100 |
Why?
| Ketamine | 1 | 2012 | 65 | 0.100 |
Why?
| Severity of Illness Index | 2 | 2012 | 1029 | 0.100 |
Why?
| Vancomycin | 1 | 2012 | 85 | 0.100 |
Why?
| Neutropenia | 1 | 2012 | 120 | 0.100 |
Why?
| Cellulitis | 1 | 2011 | 14 | 0.100 |
Why?
| Nitroimidazoles | 1 | 2011 | 17 | 0.100 |
Why?
| Anemia, Hemolytic | 1 | 2011 | 12 | 0.100 |
Why?
| Sex Factors | 1 | 2014 | 765 | 0.100 |
Why?
| Receptor, Cannabinoid, CB1 | 1 | 2012 | 127 | 0.100 |
Why?
| Rhabdomyolysis | 1 | 2011 | 15 | 0.100 |
Why?
| Hair | 1 | 2011 | 31 | 0.090 |
Why?
| Neuroprotective Agents | 1 | 2012 | 132 | 0.090 |
Why?
| Hypertension | 2 | 2015 | 550 | 0.090 |
Why?
| Coloring Agents | 1 | 2010 | 81 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 175 | 0.090 |
Why?
| Kidney Transplantation | 1 | 2012 | 190 | 0.090 |
Why?
| Muscular Diseases | 1 | 2011 | 61 | 0.090 |
Why?
| Brain Injuries | 1 | 2012 | 185 | 0.090 |
Why?
| Interleukin-10 | 2 | 2012 | 97 | 0.090 |
Why?
| Immunoblotting | 1 | 2010 | 128 | 0.090 |
Why?
| Liver Circulation | 1 | 2010 | 29 | 0.090 |
Why?
| Play and Playthings | 1 | 2009 | 13 | 0.090 |
Why?
| Butylene Glycols | 1 | 2009 | 14 | 0.090 |
Why?
| Sodium Oxybate | 1 | 2009 | 13 | 0.090 |
Why?
| Coma | 1 | 2009 | 17 | 0.090 |
Why?
| Linear Models | 2 | 2012 | 306 | 0.090 |
Why?
| Blood Pressure | 1 | 2012 | 553 | 0.080 |
Why?
| Databases as Topic | 1 | 2009 | 43 | 0.080 |
Why?
| Immunosuppressive Agents | 1 | 2011 | 235 | 0.080 |
Why?
| Environmental Exposure | 1 | 2011 | 213 | 0.080 |
Why?
| Kidney Diseases | 1 | 2012 | 282 | 0.080 |
Why?
| Foreign Bodies | 1 | 2009 | 66 | 0.080 |
Why?
| Drug Compounding | 1 | 2008 | 26 | 0.080 |
Why?
| Blood Chemical Analysis | 1 | 2008 | 32 | 0.080 |
Why?
| Cesium | 1 | 2008 | 8 | 0.080 |
Why?
| Incidence | 1 | 2012 | 1084 | 0.080 |
Why?
| Analgesics, Opioid | 1 | 2014 | 550 | 0.080 |
Why?
| Probability | 1 | 2008 | 181 | 0.080 |
Why?
| Chlorides | 1 | 2008 | 55 | 0.080 |
Why?
| Macrophages | 2 | 2017 | 400 | 0.080 |
Why?
| Chloroform | 1 | 2007 | 7 | 0.080 |
Why?
| DNA | 1 | 2011 | 602 | 0.080 |
Why?
| Free Radical Scavengers | 2 | 2011 | 33 | 0.080 |
Why?
| Models, Statistical | 1 | 2009 | 247 | 0.080 |
Why?
| Magnetic Resonance Imaging | 2 | 2012 | 1645 | 0.070 |
Why?
| Infusions, Intravenous | 2 | 2023 | 227 | 0.070 |
Why?
| Sulfuric Acids | 1 | 2006 | 8 | 0.070 |
Why?
| Acute Kidney Injury | 1 | 2011 | 377 | 0.070 |
Why?
| Aerobiosis | 1 | 2006 | 15 | 0.070 |
Why?
| Electrocardiography | 1 | 2008 | 281 | 0.070 |
Why?
| Genotype | 3 | 2018 | 606 | 0.070 |
Why?
| Emergency Medicine | 1 | 2006 | 52 | 0.070 |
Why?
| Analysis of Variance | 1 | 2007 | 638 | 0.070 |
Why?
| Hepatitis C, Chronic | 2 | 2018 | 82 | 0.070 |
Why?
| Toxicity Tests | 1 | 2006 | 55 | 0.070 |
Why?
| Reproducibility of Results | 3 | 2015 | 1289 | 0.060 |
Why?
| Antioxidants | 2 | 2023 | 284 | 0.060 |
Why?
| Phosphorylation | 2 | 2019 | 595 | 0.060 |
Why?
| Cell Nucleus | 1 | 2006 | 206 | 0.060 |
Why?
| Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| Mitochondrial Membrane Transport Proteins | 1 | 2004 | 21 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 302 | 0.060 |
Why?
| Mice, Transgenic | 2 | 2018 | 637 | 0.060 |
Why?
| Child Abuse | 1 | 2006 | 152 | 0.060 |
Why?
| Receptors, Progesterone | 1 | 2024 | 66 | 0.060 |
Why?
| Kupffer Cells | 1 | 2003 | 15 | 0.060 |
Why?
| Glutathione Disulfide | 1 | 2003 | 45 | 0.060 |
Why?
| Single-Blind Method | 2 | 2015 | 121 | 0.060 |
Why?
| Models, Chemical | 2 | 2015 | 71 | 0.060 |
Why?
| Superoxides | 1 | 2003 | 54 | 0.060 |
Why?
| Computer Simulation | 2 | 2017 | 327 | 0.060 |
Why?
| Pyruvic Acid | 1 | 2023 | 22 | 0.060 |
Why?
| Alanine | 1 | 2023 | 47 | 0.060 |
Why?
| Receptors, Estrogen | 1 | 2024 | 144 | 0.060 |
Why?
| Omeprazole | 1 | 2003 | 18 | 0.060 |
Why?
| Risk Assessment | 1 | 2008 | 1349 | 0.060 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 27 | 0.060 |
Why?
| Injections, Intraperitoneal | 1 | 2003 | 62 | 0.060 |
Why?
| Immunoenzyme Techniques | 1 | 2003 | 160 | 0.060 |
Why?
| Safety | 1 | 2003 | 89 | 0.060 |
Why?
| Radiographic Image Enhancement | 1 | 2003 | 31 | 0.060 |
Why?
| Prognosis | 3 | 2015 | 2083 | 0.060 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 143 | 0.050 |
Why?
| Tibial Fractures | 1 | 2003 | 33 | 0.050 |
Why?
| Oxygen | 1 | 2006 | 361 | 0.050 |
Why?
| Pediatrics | 1 | 2006 | 304 | 0.050 |
Why?
| Genetic Variation | 1 | 2024 | 245 | 0.050 |
Why?
| Drug Interactions | 1 | 2003 | 224 | 0.050 |
Why?
| Molecular Structure | 2 | 2013 | 318 | 0.050 |
Why?
| Logistic Models | 2 | 2018 | 986 | 0.050 |
Why?
| Membrane Potential, Mitochondrial | 2 | 2015 | 46 | 0.050 |
Why?
| Hydroxylation | 2 | 2012 | 62 | 0.050 |
Why?
| Antibodies, Viral | 1 | 2022 | 112 | 0.050 |
Why?
| Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2003 | 285 | 0.050 |
Why?
| Neoplasms | 1 | 2012 | 1349 | 0.050 |
Why?
| Death, Sudden, Cardiac | 1 | 2022 | 56 | 0.050 |
Why?
| Psychotropic Drugs | 1 | 2022 | 84 | 0.050 |
Why?
| Nitric Oxide | 1 | 2003 | 294 | 0.050 |
Why?
| Databases, Factual | 1 | 2024 | 710 | 0.050 |
Why?
| Uncertainty | 1 | 2021 | 47 | 0.050 |
Why?
| Kidney Failure, Chronic | 1 | 2003 | 226 | 0.050 |
Why?
| Gestational Age | 2 | 2012 | 444 | 0.040 |
Why?
| Anti-Asthmatic Agents | 1 | 2020 | 34 | 0.040 |
Why?
| Apoptosis | 1 | 2006 | 1295 | 0.040 |
Why?
| Australia | 1 | 2019 | 85 | 0.040 |
Why?
| Decision Making | 1 | 2002 | 290 | 0.040 |
Why?
| Risk Factors | 3 | 2012 | 3927 | 0.040 |
Why?
| Tissue Distribution | 2 | 2013 | 179 | 0.040 |
Why?
| Research Design | 1 | 2021 | 379 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 166 | 0.040 |
Why?
| Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| Qualitative Research | 1 | 2021 | 358 | 0.040 |
Why?
| Metagenomics | 1 | 2018 | 40 | 0.040 |
Why?
| Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 103 | 0.040 |
Why?
| Drug Dosage Calculations | 1 | 2018 | 11 | 0.040 |
Why?
| Acute-Phase Reaction | 1 | 2018 | 9 | 0.040 |
Why?
| RNA, Viral | 1 | 2018 | 128 | 0.040 |
Why?
| Ethics, Research | 1 | 2017 | 41 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2018 | 83 | 0.040 |
Why?
| DNA, Viral | 1 | 2018 | 150 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 99 | 0.040 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 2011 | 73 | 0.040 |
Why?
| Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.040 |
Why?
| Glucuronides | 1 | 2017 | 46 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 110 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2018 | 131 | 0.040 |
Why?
| Communication | 1 | 2019 | 273 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 200 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 198 | 0.040 |
Why?
| Residence Characteristics | 1 | 2017 | 161 | 0.030 |
Why?
| Rats | 2 | 2014 | 3610 | 0.030 |
Why?
| Liver Diseases, Alcoholic | 1 | 2016 | 36 | 0.030 |
Why?
| Oscillometry | 1 | 2015 | 9 | 0.030 |
Why?
| NAD | 1 | 2015 | 44 | 0.030 |
Why?
| Health Literacy | 1 | 2017 | 132 | 0.030 |
Why?
| Sex Characteristics | 1 | 2017 | 213 | 0.030 |
Why?
| Diastole | 1 | 2015 | 76 | 0.030 |
Why?
| Systole | 1 | 2015 | 72 | 0.030 |
Why?
| Binding, Competitive | 1 | 2015 | 114 | 0.030 |
Why?
| Arm | 1 | 2015 | 54 | 0.030 |
Why?
| Observer Variation | 1 | 2015 | 139 | 0.030 |
Why?
| Registries | 1 | 2018 | 555 | 0.030 |
Why?
| Patient Safety | 1 | 2016 | 118 | 0.030 |
Why?
| Substrate Specificity | 1 | 2015 | 215 | 0.030 |
Why?
| Clinical Protocols | 1 | 2015 | 120 | 0.030 |
Why?
| Suramin | 1 | 2014 | 14 | 0.030 |
Why?
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2014 | 20 | 0.030 |
Why?
| Antigens, Ly | 1 | 2014 | 10 | 0.030 |
Why?
| Islets of Langerhans | 1 | 2014 | 26 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 195 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2014 | 65 | 0.030 |
Why?
| Oxygen Consumption | 1 | 2015 | 213 | 0.030 |
Why?
| Cell Proliferation | 1 | 2019 | 1073 | 0.030 |
Why?
| Algorithms | 1 | 2018 | 685 | 0.030 |
Why?
| Gene Silencing | 1 | 2014 | 125 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2014 | 87 | 0.030 |
Why?
| Biological Availability | 2 | 2005 | 132 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Capsules | 1 | 2013 | 34 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 17 | 0.030 |
Why?
| Powders | 1 | 2013 | 30 | 0.030 |
Why?
| Brain | 2 | 2012 | 1420 | 0.030 |
Why?
| Glutathione Transferase | 1 | 2014 | 194 | 0.030 |
Why?
| Body Temperature Regulation | 1 | 2013 | 35 | 0.030 |
Why?
| Ethanol | 1 | 2016 | 363 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 65 | 0.030 |
Why?
| Heterozygote | 1 | 2012 | 88 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 220 | 0.030 |
Why?
| Drug Resistance | 1 | 2012 | 73 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 61 | 0.030 |
Why?
| Amine Oxidase (Copper-Containing) | 1 | 2012 | 4 | 0.030 |
Why?
| Placebo Effect | 1 | 2012 | 18 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 86 | 0.030 |
Why?
| Intention to Treat Analysis | 1 | 2012 | 29 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 27 | 0.030 |
Why?
| Calcitonin Gene-Related Peptide | 1 | 2012 | 24 | 0.030 |
Why?
| Prescription Drugs | 1 | 2012 | 42 | 0.030 |
Why?
| Histamine | 1 | 2012 | 26 | 0.030 |
Why?
| Cell Survival | 1 | 2014 | 675 | 0.030 |
Why?
| Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 870 | 0.030 |
Why?
| Calcitonin | 1 | 2012 | 38 | 0.030 |
Why?
| Protein Precursors | 1 | 2012 | 49 | 0.030 |
Why?
| Fever | 1 | 2013 | 122 | 0.030 |
Why?
| Population | 1 | 2012 | 9 | 0.030 |
Why?
| Glucose | 1 | 2014 | 368 | 0.030 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2012 | 64 | 0.030 |
Why?
| Office Visits | 1 | 2012 | 47 | 0.030 |
Why?
| Dopamine | 1 | 2013 | 199 | 0.030 |
Why?
| Ligands | 1 | 2012 | 226 | 0.030 |
Why?
| Genetic Association Studies | 1 | 2012 | 131 | 0.030 |
Why?
| Expectorants | 1 | 2011 | 14 | 0.030 |
Why?
| Hyperthermia, Induced | 1 | 2013 | 123 | 0.030 |
Why?
| Risk | 1 | 2012 | 340 | 0.020 |
Why?
| Glucuronic Acid | 1 | 2011 | 9 | 0.020 |
Why?
| Creatinine | 1 | 2012 | 160 | 0.020 |
Why?
| Microsomes | 1 | 2011 | 46 | 0.020 |
Why?
| Deuterium | 1 | 2011 | 42 | 0.020 |
Why?
| Central Nervous System | 1 | 2012 | 91 | 0.020 |
Why?
| Reference Standards | 1 | 2011 | 61 | 0.020 |
Why?
| Monte Carlo Method | 1 | 2012 | 97 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 99 | 0.020 |
Why?
| ROC Curve | 1 | 2012 | 254 | 0.020 |
Why?
| Birth Weight | 1 | 2012 | 127 | 0.020 |
Why?
| Syndrome | 1 | 2012 | 255 | 0.020 |
Why?
| Forensic Toxicology | 1 | 2011 | 6 | 0.020 |
Why?
| Muscular Dystrophies | 1 | 2011 | 15 | 0.020 |
Why?
| Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| Spinal Muscular Atrophies of Childhood | 1 | 2011 | 8 | 0.020 |
Why?
| Cytoplasm | 1 | 2011 | 102 | 0.020 |
Why?
| Glucuronidase | 1 | 2011 | 50 | 0.020 |
Why?
| Crime | 1 | 2011 | 27 | 0.020 |
Why?
| Protein Isoforms | 1 | 2011 | 122 | 0.020 |
Why?
| C-Reactive Protein | 1 | 2012 | 158 | 0.020 |
Why?
| Transaminases | 1 | 2011 | 12 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 104 | 0.020 |
Why?
| Forecasting | 1 | 2012 | 166 | 0.020 |
Why?
| Multivariate Analysis | 1 | 2012 | 645 | 0.020 |
Why?
| Bilirubin | 1 | 2011 | 45 | 0.020 |
Why?
| Intensive Care Units | 1 | 2012 | 218 | 0.020 |
Why?
| Double-Blind Method | 1 | 2012 | 738 | 0.020 |
Why?
| Child Development | 1 | 2012 | 210 | 0.020 |
Why?
| Blotting, Western | 1 | 2011 | 671 | 0.020 |
Why?
| Suction | 1 | 2009 | 23 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 707 | 0.020 |
Why?
| Intensive Care Units, Pediatric | 1 | 2011 | 191 | 0.020 |
Why?
| Intestines | 1 | 2011 | 202 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 258 | 0.020 |
Why?
| Eating | 1 | 2009 | 169 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2013 | 1764 | 0.020 |
Why?
| Alcohol Drinking | 1 | 2011 | 263 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 495 | 0.020 |
Why?
| Survival Rate | 1 | 2011 | 950 | 0.020 |
Why?
| Kidney | 1 | 2013 | 803 | 0.020 |
Why?
| Alcoholism | 1 | 2011 | 255 | 0.020 |
Why?
| Nitric Oxide Synthase | 1 | 2007 | 98 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 828 | 0.020 |
Why?
| Carcinoma, Hepatocellular | 1 | 2008 | 200 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2008 | 345 | 0.010 |
Why?
| Follow-Up Studies | 1 | 2009 | 2371 | 0.010 |
Why?
| Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 32 | 0.010 |
Why?
| Specialization | 1 | 2003 | 47 | 0.010 |
Why?
| Medicine | 1 | 2003 | 61 | 0.010 |
Why?
| Endopeptidases | 1 | 2002 | 75 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2003 | 524 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|